Back to search

Article

Preclinical Assessment in Transgenic NOD Mice of a Novel Immunotherapy for Type 1 Diabetes: Lipoplexes down Modulate the Murine C1858T <em>Ptpn22</em> Variant <em>In </em><em>Vitro</em>

2025-10-11

Abstract excerpt

The C1858T PTPN22 (R620W) variant has been implicated in the pathogenesis of several autoimmune disorders and represents a promising immunotherapeutic target for Type 1 diabetes. We have been implementing a novel immunotherapeutic approach based on the use of lipoplexes that deliver siRNA duplexes. Efficacy and safety of lipoplexes halting variant expression was demonstrated in the peripheral blood of patients in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0cc0e875-5bf6-5a86-9747-38bf6624d30c
DOI
10.20944/preprints202510.0849.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Preclinical Assessment in Transgenic NOD Mice of a Novel Immunotherapy for Type 1 Diabetes: Lipoplexes down Modulate the Murine C1858T <em>Ptpn22</em> Variant <em>In </em><em>Vitro</em>DOI 10.20944/preprints202510.0849.v1
Select a neighboring publication to make it the new centre.